Rym Ben-Hamadi
Analysis Group
29 Papers
193 Citations
Rym Ben-Hamadi is an academic researcher from Analysis Group. The author has contributed to research in topics: Escitalopram & Major depressive disorder. The author has an hindex of 12, co-authored 29 publications.
Chat about Author
Papers
Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance
Howard G. Birnbaum,Ronald C. Kessler,B S David Kelley,Rym Ben-Hamadi,Vijay N. Joish,Paul E. Greenberg +5 more
TL;DR: MDD severity is significantly associated with increased treatment usage/costs, treatment adequacy, unemployment, and disability and with reduced work performance.
394
The economic consequences of irritable bowel syndrome: a US employer perspective.
Stephanie A. Leong,Victoria Barghout,Howard G. Birnbaum,Crystal Thibeault,Rym Ben-Hamadi,Feride Frech,Joshua J. Ofman +6 more
TL;DR: Irritable bowel syndrome is a significant financial burden on the employer that arises from an increase in direct and indirect costs compared with the control group.
169
Annual costs associated with diagnosis of uterine leiomyomata.
Katherine E Hartmann,Howard G. Birnbaum,Rym Ben-Hamadi,Eric Q. Wu,Max H. Farrell,James Spalding,Paul E. Stang +6 more
TL;DR: Diagnosed uterine leiomyomata are associated with increased resource use and with substantially higher health care and work loss costs.
118
Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.
Eric Q. Wu,Paul Hodgkins,Rym Ben-Hamadi,Juliana Setyawan,Jipan Xie,Vanja Sikirica,Ella X Du,Sherry Y. Yan,M. Haim Erder +8 more
TL;DR: There was consistent evidence that pharmacotherapies are cost effective compared with no treatment or behavioural therapy among children and adolescents with ADHD, and more economic evaluations with standardized methods, such as effectiveness measures and cost components, are warranted.
57
Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.
TL;DR: Geriatric patients treated with escitalopram had higher treatment persistence, fewer hospitalization days and lower total healthcare costs than patients on other SSRI/SNRIs after controlling for baseline characteristics.
27